Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10966-10975

  McIlhatton, Michael A ^a   Tyler, Jessica ^a   Burkholder, Susan ^b   Ruschoff, Josef ^c   Rigas, Basil ^d   Kopelovich, Levy ^e   Fishel, Richard ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c KLINIKUM KASSEL   (Germany)

^d STONY BROOK UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ARTICLE; CANCER CELL; COLORECTAL CANCER; DRUG INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASPIRIN; BASE PAIR MISMATCH; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; NITRIC OXIDE;

EID: 36348936281     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2562     Document Type: Article

References (31)

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
2. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004;10:324-30.
3. Kashfi K, Ryan Y, Qiao LL, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002;303:1273-82.
4. Williams JL, Nath N, Chen J, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and β-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003;63:7613-8.
5. Yeh RK, Chen J, Williams JL, et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 2004;67:2197-205.
6. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 2002;67:107-20.
7. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 2005;314:1-8.
8. Bak AW, McKnight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998;62:PL367-73.
9. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 2004;313:784-8.
10. Rao CV, Reddy BS, Steele VE, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5:1530-8.
11. Ouyang N, Williams JL, Tsioulias GJ, et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 2006;66:4503-11.
12. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003;124:600-7.
13. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev 2006;106:302-23.
14. Fishel R, Acharya S, Berardini M, et al. Signaling mismatch repair: the mechanics of an adenosine-nucleotide molecular switch. Cold Spring Harbor Symp Quant Biol 2000;65:217-24.
15. Peltomaki P. Lynch syndrome genes. Fam Cancer 2005;4:227-32.
16. Boland CR, Fishel R. Lynch syndrome: form, function, proteins, and basketball. Gastroenterology 2005;129:751-5.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. [Review, 119 refs]. Cancer Res 1998;58:5248-57.
18. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
19. Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A 1998;95:11301-6.
20. McCurrach ME, Lowe SW. Methods for studying proand antiapoptotic genes in nonimmortal cells. Methods Cell Biol 2001;66:197-227.
21. -/- colonocytes. Cancer Res 1999;59:5882-6.
22. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308-12.
23. Kabbarah O, Mallon MA, Pfeifer JD, Edelmann W, Kucherlapati R, Goodfellow PJ. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinog 2003;38:155-9.
24. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001;22:1931-7.
25. Streisinger G, Owen J. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics 1985;109:633-59.
26. Meyers M, Theodosiou M, Acharya S, et al. Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. Cancer Res 1997;57:206-8.
27. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
28. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997;57:4749-56.
29. Papadopoulos N, Nicolaides NC, Liu B, et al. Mutations of GTBP in genetically unstable cells. Science 1995;268:1915-7.
30. Wei K, Clark AB, Wong E, et al. Inactivation of exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 2003;17:603-14.
31. Sevignani C, Wlodarski P, Kirillova J, et al. Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene. J Clin Invest 1998;101:1572-80.